Microbial Bioburden on Oral Solid Dosage Forms
News
Article
Pharmaceutical TechnologyPharmaceutical Technology-02-02-2002
Volume 26
Issue 2
Low levels of some microorganisms that are present in oral solid dosage forms are unlikely to present a risk to patients. The amount of water activity in these products can help determine when microbiological testing should be conducted.
Articles in this issue
Using Earned-Value Analysis to Better Manage Projects
Microbial Bioburden on Oral Solid Dosage Forms
Overview of Technologies Supporting Security Requirements in 21 CFR Part 11, Part I
Modernizing Pharmaceutical Manufacturing
The Role of Computational Fluid Dynamics in the Pharmaceutical Industry
Available Guidance and Best Practices for Conducting Forced Degradation Studies
Outsourcing Outlook
Effect of Formulation and Process Variables on Matrix Erosion and Drug Release from a Multiunit Erosion Matrix of a Poorly Soluble Drug
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
